Topline data were announced from a phase 3 trial evaluating CagriSema in overweight or obese patients without type 2 diabetes.

Maridebart cafraglutide, a novel injectable GLP-1 receptor agonist/GIP receptor antagonist, reduced body weight by up to ...

The best semaglutide dose for weight loss varies according to your starting weight, risks, and stage of treatment. Read to ...

As GLP-1 RA use soars, experts are worried that patients may not be getting the right nutrients in their diets. How can ...

Naturally, more work is needed. Although GLS -1 agonists have been used in diabetes for 20 years, some of the newer findings ...

Sciwind has granted Verdiva the exclusive global rights to develop, manufacture and commercialize the partnered programs outside of greater China and South Korea. Sciwind has retained the rights to ...

The drug's development was funded by Novo Nordisk, the maker of popular semaglutide drugs like Ozempic and Wegovy. While ...

Browse in-depth TOC on " Global Biotechnology industry Outlook " 10 - Tables 20 - Figures 70 - Pages . The Global Biotech ...

With over $410 million in financing; to advance portfolio of next-gen oral and injectable treatments with first- or ...

Over her three-decade career, weight management physician Dr. Sarah Ro has seen hundreds of patients. Many of them are on ...

MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that it is holding an Advisory Committee meeting today, at the 9th ...

Novartis faces short-term challenges with patent expirations but shows long-term growth potential, making the stock a buy ...